The New York Stock Exchange ended the session with Pfizer jumping 3.51% to $40.79 on Wednesday, after three consecutive sessions in a row of gains. The New York Stock Exchange jumped 0.29% to $14,188.20, following yesterday's upward trend on what was a somewhat positive trend trading session today.
Pfizer today's close was $40.79, 1.50% below its 52-week high of $41.40.
News about Pfizer today
Pfizer-biontech coronavirs vaccine gains approval for use in the UK. According to today's article on ForexLive, "UK says that the vaccine will be made available starting from next week
This has been widely anticipated but it adds to the optimism and buzz surrounding vaccine developments."
Pfizer says US FDA and EU EMA decisions on authorisation expected this month as well. According to today's article on ForexLive, "Pfizer briefs after the UK MHRA authorises emergency-use supply for its coronavirus vaccine
The pharmaceutical firm also confirms that companies are ready to deliver the first doses to the UK immediately."
Pfizer, biontech's covid-19 vaccine wins u.k. authorization. According to today's article on The Wall Street Journal, "Britain became the first Western nation to grant emergency-use authorization for a Covid-19 vaccine, clearing a shot developed by Pfizer and Germanyâs BioNTech to be distributed in limited numbers within days.."
According to today's article on The Wall Street Journal, "Salesforce.com, Pfizer, biontech" are stocks to watch today.
According to today's article on Bloomberg Quint, "Vaccine-Tied Stocks Flail After U.K"
Pfizer's Sales
Pfizer's sales growth is a negative 9.7% for the current quarter and a decline by 9.1% for the next. The company's growth estimates for the ongoing quarter and the next is a negative 12.7% and a negative 12.5%, respectively.
Pfizer's Revenue
Year-on-year quarterly revenue growth declined by 4.3%, now sitting on 48.65B for the twelve trailing months.
Pfizer's Stock Top and Bottom Yearly Value
Pfizer's stock is valued at $40.79 at 16:57 EST, below its 52-week high of $41.40 and way above its 52-week low of $26.45.
Pfizer's Moving Average
Pfizer's worth is way higher than its 50-day moving average of $35.78 and way higher than its 200-day moving average of $34.84.
Previous days news about Pfizer
According to yesterday's article on Bloomberg Quint, "Pfizer, BioNTech Seek Clearance to Sell Covid Vaccine in Europe."
According to yesterday's article on Bloomberg Quint, "Pfizer, biontech seek EU clearance for covid-19 vaccine. "
Pfizer-biontech seeks EU clearance for coronavirus vaccine. According to yesterday's article on ForexLive, "Pfizer vaccine can be in use in the EU by the year-end if cleared. Pfizer-BioNTech just announced that they have submitted an application to the EMA today to seek clearance for coronavirus vaccine use in the EU.."
Pfizer, biontech file for covid-19 vaccine approval in europe. According to yesterday's article on The Wall Street Journal, "Pfizer and partner BioNTech said they are seeking approval from the European Union for their coronavirus vaccine."
Pfizer, biontech apply for CMA in europe for covid-19 vaccine candidate. According to yesterday's article on MarketWatch, "Shares of Pfizer Inc"
Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
